Retagliptin (phosphate)

Retagliptin phosphate (SP2086 phosphate) is a selective, competitive and orally active dipeptidyl peptidase-4 (DPP-4) inhibitor. Retagliptin phosphate can be used for type 2 diabetes mellitus (T2DM) research[1].

Product Specifications

CAS Number

[1256756-88-3]

Product Name Alternative

SP2086 (phosphate)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Dipeptidyl Peptidase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/Retagliptin_Phosphate.html

Purity

99.71

Solubility

DMSO : ≥ 150 mg/mL

Smiles

O=C(C1=C2CN(C(C[C@H](N)CC3=CC(F)=C(F)C=C3F)=O)CCN2C(C(F)(F)F)=N1)OC.O=P(O)(O)O

Molecular Formula

C19H21F6N4O7P

Molecular Weight

562.36

Precautions

H302, H315, H319, H335

References & Citations

[1]Hu C, et al. Pharmacokinetics of Phosphate Retagliptin Tabletin in Patients with Renal Dysfunction. Sichuan Da Xue Xue Bao Yi Xue Ban. 2018 Jan;49 (1) :74-80.|[2]Avivit Cahn, et al. An update on DPP-4 inhibitors in the management of type 2 diabetes. Expert Opin Emerg Drugs. 2016 Dec;21 (4) :409-419.